© 2021 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.
Julio Gagné serves as vice president of program and alliance management at Travere Therapeutics and is a member of the executive team. He joined the company in 2016. With more than 20 years of experience in drug development, Mr. Gagné is responsible for overseeing each of the company’s approved product and pipeline programs that are governed by a cross-functional matrix team. Additionally, he manages relationships with partners/alliances, directs strategy, timelines and risk mitigation for development molecules, and oversees governance boards, quarterly business reviews and due diligence processes for late-stage business development.
Previously, Mr. Gagné served in executive leadership roles in program management and asset strategy at Immunogen, Bristol-Myers Squibb, Antisoma and Novartis Oncology. Earlier in his career, Mr. Gagné also held leadership roles in program management at BioMarin, Onyx Pharmaceuticals and Amgen. Mr Gagné earned a bachelor’s degree in biochemistry from University of California, Berkeley, and master’s in business administration in finance from San Francisco State University.
